These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 32526313)
21. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. Ferreira S; Guttman-Yassky E; Torres T Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305 [TBL] [Abstract][Full Text] [Related]
22. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. Tauber M; Apoil PA; Richet C; Laurent J; De Bonnecaze G; Mouchon E; Cassagne M; Marguery MC; Hegazy S; Konstantinou MP; Severino M; Uthurriague C; Giordano-Labadie F; Didier A; Paul C Br J Dermatol; 2019 Jun; 180(6):1551-1552. PubMed ID: 30633329 [No Abstract] [Full Text] [Related]
23. Characterization of T cell subsets in patients with atopic dermatitis using OKT monoclonal antibodies. Miadonna A; Tedeschi A; Leggieri E; Cottini M; Menni S; Froldi M; Zanussi C Ann Allergy; 1985 Apr; 54(4):321-4. PubMed ID: 3157336 [TBL] [Abstract][Full Text] [Related]
24. Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis. Cheng J; Jiang L; Morrow NC; Avdic A; Fairley JA; Ling JJ; Greiner MA J Am Acad Dermatol; 2021 Jul; 85(1):265-267. PubMed ID: 32956738 [No Abstract] [Full Text] [Related]
25. Use of dupilumab for atopic dermatitis in pediatric and young adult patients with inborn errors of immunity. Zangari P; Giancotta C; Pacillo L; Colantoni N; Leone F; Amodio D; Santilli V; Manno EC; Cotugno N; Rivalta B; Rotulo GA; Di Cesare S; Diociaiuti A; El Hachem M; Cancrini C; Finocchi A; Palma P Pediatr Allergy Immunol; 2024 Aug; 35(8):e14215. PubMed ID: 39105363 [No Abstract] [Full Text] [Related]
26. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review. Raffi J; Suresh R; Botto N; Murase JE J Am Acad Dermatol; 2020 Jan; 82(1):132-138. PubMed ID: 31562940 [TBL] [Abstract][Full Text] [Related]
27. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV. Lor M; Villa N; Holland V Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092 [TBL] [Abstract][Full Text] [Related]
28. [Psoriasis in dupilumab-treated atopic dermatitis]. Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945 [TBL] [Abstract][Full Text] [Related]
29. Imbalance of CD4+CD45R+ and CD4+CD29+ T helper cell subsets in patients with atopic diseases. Schauer U; Jung T; Heymanns J; Rieger CH Clin Exp Immunol; 1991 Jan; 83(1):25-9. PubMed ID: 1703056 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of innate lymphoid cells and their subsets in atopic dermatitis patients with and without dupilumab therapy. Čelakovská J; Čermáková E; Boudkova P; Krejsek J J Dermatolog Treat; 2024 Dec; 35(1):2299721. PubMed ID: 38174384 [No Abstract] [Full Text] [Related]
31. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Napolitano M; Fabbrocini G; Scalvenzi M; Blasio C; Stingeni L; Patruno C Clin Exp Dermatol; 2020 Oct; 45(7):888-890. PubMed ID: 32365237 [TBL] [Abstract][Full Text] [Related]
32. T helper cell subsets in the development of atopic dermatitis. Turner MJ; Travers JB; Kaplan MH J Drugs Dermatol; 2012 Oct; 11(10):1174-8. PubMed ID: 23134982 [TBL] [Abstract][Full Text] [Related]
33. Flow cytometric detection of type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-5) cytokines in T-helper and T-suppressor/cytotoxic cells in rheumatoid arthritis, allergic asthma and atopic dermatitis. Schuerwegh AJ; De Clerck LS; De Schutter L; Bridts CH; Verbruggen A; Stevens WJ Cytokine; 1999 Oct; 11(10):783-8. PubMed ID: 10525317 [TBL] [Abstract][Full Text] [Related]
34. Dupilumab for Atopic Dermatitis, a Possible Risk Factor of Juvenile Ischemic Stroke: A Case Report. Iwase R; Ishiguro T; Fujita K; Ishibashi S; Yokota T J Stroke Cerebrovasc Dis; 2020 Jun; 29(6):104763. PubMed ID: 32265139 [TBL] [Abstract][Full Text] [Related]
35. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients. Ludriksone L; Elsner P; Schliemann S J Dtsch Dermatol Ges; 2019 Dec; 17(12):1278-1280. PubMed ID: 31829527 [No Abstract] [Full Text] [Related]
37. The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis. Honstein T; Werfel T Curr Opin Allergy Clin Immunol; 2020 Aug; 20(4):386-394. PubMed ID: 32452891 [TBL] [Abstract][Full Text] [Related]
38. Dupilumab for treatment of severe atopic dermatitis in a heart transplant recipient. Hamid RN; Bomar L; Strowd L Cutis; 2019 Jun; 103(6):E1-E2. PubMed ID: 31348459 [No Abstract] [Full Text] [Related]
39. The cellular orchestra in skin allergy; are differences to lung and nose relevant? Akdis M Curr Opin Allergy Clin Immunol; 2010 Oct; 10(5):443-51. PubMed ID: 20736733 [TBL] [Abstract][Full Text] [Related]
40. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]